MedPath

Impact of Acute Kidney Injury on Sarcopenia and Frailty in Patients With Liver Cirrhosis

Conditions
Sarcopenia
Frailty
Cirrhosis
Kidney Injury
Registration Number
NCT05389280
Lead Sponsor
Kangbuk Samsung Hospital
Brief Summary

The aim of this prospective observational study is to evaluate the impact of acute kidney injury on sarcopenia and frailty in patients with liver cirrhosis.

Detailed Description

The aim of this prospective study is to collect data on patients with liver cirrhosis and to investigate the impact of acute kidney injury on sarcopenia and frailty in patients with liver cirrhosis. If patients agree to participate in this clinical trial, the patients' data (such as age, sex, height, weight, nutrition status \[RFH-NPT\], history of medication, laboratory findings, endoscopic findings, and radiologic findings) will be collected in a research database. Renal injury was measured using conventional and novel serum biomarkers (serum creatinine, cystatin-C, neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, and interleukin-18. Sarcopenia was evaluated using skeletal muscle index on abdominal computed tomography. Frailty was measured using Liver Frailty Index. The research database will be updated to include data on patients' disease outcomes and follow-up care.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Liver cirrhosis
  • aged over 20 years
Exclusion Criteria
  • serum creatinine >1.5 mg/dL
  • on dialysis
  • liver transplant

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Participants with Acute kidney injuryup to 24 weeks

an increase in SCr of 0.3 mg/dL (26.4 µmoL/L) in \<48 hours, or a 50% increase in SCr from a baseline within ≤3 months

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Kangbuk Samsung Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath